Evidence map›Paper›PMID 32944083›Full record

ArticleThyroid research2020

Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? - experience of the Brugmann hospital in Brussels.

Laura Iconaru, Felicia Baleanu, Georgiana Taujan, Ruth Duttmann, Linda Spinato, Rafik Karmali, Pierre Bergmann, Anne-Sophie Hambye

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thyroid research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Laura IconaruDepartment of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, Place van Gehuchten4, 1020 Laeken, Brussels, Belgium.ORCID 0000-0001-8505-9324
Felicia BaleanuDepartment of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, Place van Gehuchten4, 1020 Laeken, Brussels, Belgium.
Georgiana TaujanDepartment of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, Place van Gehuchten4, 1020 Laeken, Brussels, Belgium.
Ruth DuttmannDepartment of Anatomopathology, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Linda SpinatoDepartment of Otorhinolaryngology, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Rafik KarmaliDepartment of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, Place van Gehuchten4, 1020 Laeken, Brussels, Belgium.
Pierre BergmannDepartment of Nuclear Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Anne-Sophie HambyeDepartment of Nuclear Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Université Libre de Bruxelles · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background131-iodine (

methodsPatients treated and followed up for DTC according to the 2014-ATA guidelines (Group 2) were compared to those treated between 2007 and 2014 (Group 1) in terms of general characteristics, risk of recurrence (based on the 2015-ATA recommendations), preparation to

resultsIn total, 136 patients were included: 78 in Group 1 and 58 in Group 2. The two groups were not statistically different in terms of clinical characteristics nor risk stratification: 42.3% in Group 1 and 31% in Group 2 were classified as low risk, 38.5 and 48.3% as intermediate risk and 19.2 and 20.7% as high risk (

conclusionsUsing the 2015-ATA evidence-based guidelines for the management of DTC, meaning no

Indexed as

131-iodine therapyDifferentiated thyroid cancerTherapeutic response

Identifiers

PMID32944083
PMCPMC7488699
OpenAlexW3086573556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.